BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BD Introduces New Automated Erythrocyte Sedimentation Rate (ESR) Instrument To Help Improve Clinical Performance


12/10/2013 10:06:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Oxford, UK (10th December, 2013) – BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today introduced two new erythrocyte sedimentation rate (ESR) instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.

Erythrocyte sedimentation is a commonly used hematology test to measure inflammation and the presence and severity of disease. “Improved automation and efficiency are key to carrying out analytical tests in a busy laboratory. More and more tests are being conducted each year and reduced healthcare spending puts pressure on laboratory resources,” comments Stephen Church, European Medical Affairs, BD Diagnostics -Preanalytical Systems.

Manual ESR testing has the potential for errors during the analytical process. The new BD Sedi-20 and BD Sedi-40 combined with BD Seditainer™ tube technology, standardise analysis to improve accuracy. The BD Sedi-40 has an integrated barcode reader and tube mixer. The barcode reader ensures fast, accurate entry of sample identification information. Sample misidentification is one of the many errors which can occur during the preanalytical phase2. The integrated mixer ensures consistent and

standardised mixing of the sample, which is critical in order to obtain an accurate result. Moving from an open manual process to an automated closed process will improve healthcare worker safety by reducing the risk of exposure to blood-borne pathogens.

With an analysis time of just 30 minutes, a 50% reduction in time to result is achieved compared to the gold standard of one hour with Westergren1. BD Sedi-20 can perform 20 tests an hour and the BD Sedi-40 can perform 40 tests an hour. The BD Sedi-40 can be connected to a laboratory information system to enable automatic uploading of results.

BD Sedi-20 and Sedi-40 are being made available in Europe. For more information, contact your local BD representative – or go to: http://www.bd.com/europe/

1. Lippi G, Guidi GC, Risk management in the preanalytical phase of laboratory testing,Clin Chem Lab Med. 2007;45(6):720-7.

2. BD White paper VS9114, an evaluation of erythrocyte sedimentation rate determination using BD Sedi-20 and BD Sedi-40 in comparison to the Westergren method, 2013.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com

Product Enquiries: Heather Williams, + 44 (0) 7557 001205, Heather_williams@europe.bd.com

Press Enquiries: Laura Blott, + 44 (0) 207 402 0510, laura@lindsellmarketing.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES